JP2011521969A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521969A5
JP2011521969A5 JP2011511843A JP2011511843A JP2011521969A5 JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5 JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5
Authority
JP
Japan
Prior art keywords
composition
kinase
inhibitor
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045607 external-priority patent/WO2009146408A1/en
Publication of JP2011521969A publication Critical patent/JP2011521969A/ja
Publication of JP2011521969A5 publication Critical patent/JP2011521969A5/ja
Pending legal-status Critical Current

Links

JP2011511843A 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Pending JP2011521969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057,461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (2)

Publication Number Publication Date
JP2011521969A JP2011521969A (ja) 2011-07-28
JP2011521969A5 true JP2011521969A5 (enExample) 2011-09-08

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511843A Pending JP2011521969A (ja) 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件

Country Status (5)

Country Link
US (1) US20100087486A1 (enExample)
EP (1) EP2285380A4 (enExample)
JP (1) JP2011521969A (enExample)
CN (1) CN102083439A (enExample)
WO (1) WO2009146408A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524073A (ja) * 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
WO2012024376A1 (en) * 2010-08-17 2012-02-23 Allergan, Inc. Ep2 or ep4 agonists for treating corneal haze
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
WO2014168264A1 (ja) 2013-04-12 2014-10-16 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
MX386503B (es) 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
JP6378183B2 (ja) 2013-08-07 2018-08-22 国立大学法人京都大学 膵ホルモン産生細胞の製造法
CN121136933A (zh) 2013-09-05 2025-12-16 国立大学法人京都大学 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒
PL3064222T3 (pl) * 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki
WO2015178431A1 (ja) 2014-05-21 2015-11-26 国立大学法人京都大学 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤
CN108697793B (zh) 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
AU2017254268B2 (en) 2016-04-22 2023-03-16 Kyoto University Method for producing dopamine-producing neural precursor cells
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液
KR102594102B1 (ko) 2017-05-25 2023-10-25 고쿠리츠 다이가쿠 호진 교토 다이가쿠 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법
EP3757208A4 (en) 2018-02-19 2021-12-01 Sumitomo Dainippon Pharma Co., Ltd. CELL UNIT, MIXTURE OF CELL UNITS AND METHOD OF MANUFACTURING THEREOF
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
CA3140384A1 (en) 2019-05-15 2020-11-19 Ajinomoto Co., Inc. Method for purifying neural crest cells or corneal epithelial cells
JPWO2020235319A1 (enExample) 2019-05-20 2020-11-26
WO2021045217A1 (ja) 2019-09-06 2021-03-11 学校法人慶應義塾 グリア前駆細胞を含む細胞凝集体の製造方法
JP7619633B2 (ja) 2019-10-01 2025-01-22 国立大学法人京都大学 尿管芽先端部細胞の単離方法
JP7785351B2 (ja) 2020-03-19 2025-12-15 オリヅルセラピューティクス株式会社 心筋細胞の精製方法
EP4123015A4 (en) 2020-03-19 2024-05-22 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
EP4180516A4 (en) 2020-07-13 2024-01-17 Kyoto University SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS
JP7798294B2 (ja) 2021-01-08 2026-01-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
EP4353243A4 (en) 2021-06-10 2025-06-25 Ajinomoto Co., Inc. METHOD FOR PRODUCING MESENCHYMAL STEM CELLS
JPWO2022265086A1 (enExample) 2021-06-17 2022-12-22
EP4372075A4 (en) 2021-07-15 2025-06-11 Cellfiber Co., Ltd. Structure and use thereof
US20240318142A1 (en) 2021-08-11 2024-09-26 Kyoto University Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells
JPWO2023149407A1 (enExample) 2022-02-01 2023-08-10
CN118679244A (zh) 2022-02-09 2024-09-20 住友制药株式会社 判定培养液中的细胞在由多能干细胞向中脑底板区域的神经系统细胞的分化中的分化能力的方法
WO2023228908A1 (ja) 2022-05-23 2023-11-30 国立大学法人京都大学 腎集合管細胞および腎盂上皮細胞の製造方法
JPWO2024070494A1 (enExample) 2022-09-26 2024-04-04

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
CA2149528A1 (en) * 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antimetabolites
JPH08503969A (ja) * 1993-09-29 1996-04-30 アルコン ラボラトリーズ，インコーポレイテッド 増殖因子と組織形成抑制剤を含有する組成物
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2003057670A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003300099A1 (en) * 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
EP1633718B1 (en) * 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
US7989458B2 (en) * 2006-07-14 2011-08-02 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Similar Documents

Publication Publication Date Title
JP2011521969A5 (enExample)
JP2009280627A5 (enExample)
DK2729123T3 (en) Cannabinoidreceptorbindende funds and formations and methods
CN102821791B (zh) 透皮递送贴剂
CA2796575C (en) Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
JP2009102342A5 (enExample)
IL260579A (en) Diagnosis, prevention and treatment of joint diseases
WO2007102241A1 (ja) 外用の医薬組成物
JP2014518266A5 (enExample)
HRP20120254T1 (hr) Pripravak za produljenu lokalnu anesteziju koji sadrži saib
CN104379139A (zh) 贴附剂
TW201004617A (en) Anti-inflammatory analgesic agent for external use
JP2011516460A5 (enExample)
TW201141524A (en) Stabilized ophthalmic galactomannan formulations
CA2717948A1 (en) 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
CN105997951A (zh) 一种包含卡巴拉汀的透皮给药系统及制备方法
JP2012508256A5 (enExample)
CA2785851A1 (en) Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
RU2013130026A (ru) Смеси карнозина и гиалуроновой кислоты и их применение
JP2009532373A5 (enExample)
JP2014510156A5 (enExample)
JP2012526099A5 (enExample)
JP2011512362A5 (enExample)